Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new cash comes on the heels of results from a mid-stage obesity study treatment with the Rivus drug led to fat loss while also preserving skeletal muscle.
